Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

MediWound Ltd. (MDWD)

1.66   0.01 (0.61%) 11-25 12:59
Open: 1.65 Pre. Close: 1.65
High: 1.69 Low: 1.62
Volume: 81,483 Market Cap: 68(M)

Technical analysis

as of: 2022-11-25 1:58:42 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.97     One year: 2.3
Support: Support1: 1.41    Support2: 1.24
Resistance: Resistance1: 1.69    Resistance2: 1.97
Pivot: 1.47
Moving Average: MA(5): 1.57     MA(20): 1.45
MA(100): 1.64     MA(250): 1.93
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 85.5     %D(3): 73.4
RSI: RSI(14): 62.1
52-week: High: 3.38  Low: 1.21
Average Vol(K): 3-Month: 130 (K)  10-Days: 148 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MDWD ] has closed below upper band by 8.9%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.67 - 1.68 1.68 - 1.68
Low: 1.53 - 1.54 1.54 - 1.55
Close: 1.64 - 1.65 1.65 - 1.66

Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Headline News

Tue, 15 Nov 2022
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq

Tue, 15 Nov 2022
MediWound Misses Q3 EPS by 28c By -

Tue, 15 Nov 2022
MediWound: Q3 Earnings Snapshot - The Advocate

Tue, 15 Nov 2022
Mediwound Earnings Miss, Revenue Beats In Q3 By -

Tue, 15 Nov 2022
MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript - Seeking Alpha

Thu, 10 Nov 2022
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 41 (M)
% Held by Insiders 2.54e+007 (%)
% Held by Institutions 32.2 (%)
Shares Short 71 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.295e+007
EPS Est Next Qtl -0.19
EPS Est This Year -0.76
EPS Est Next Year -0.65
Book Value (p.s.) 0
Profit Margin (%) -80.1
Operating Margin (%) -67.2
Return on Assets (ttm) -33.1
Return on Equity (ttm) -3
Qtrly Rev. Growth 2.036e+007
Gross Profit (p.s.) -8.56
Sales Per Share 869.87
EBITDA (p.s.) 8.43269e+006
Qtrly Earnings Growth -0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow 43.15

Stock Dividends

Dividend 0
Forward Dividend 47100
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.